| Disease Domain | Count | 
|---|---|
| Endocrinology and Metabolic Disease | 1 | 
| Top 5 Drug Type | Count | 
|---|---|
| Synthetic peptide | 1 | 
| Bispecific antibody | 1 | 
| Top 5 Target | Count | 
|---|---|
| NLRP3(NACHT, LRR and PYD domains-containing protein 3) | 1 | 
| AVPR1A x AVPR1B | 1 | 
| Target | 
| Mechanism AVPR1A agonists [+1]  | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target | 
| Mechanism NLRP3 inhibitors | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target | 
| Mechanism GLP-1R agonists | 
| Active Org.- | 
| Originator Org. | 
| Active Indication- | 
| Inactive Indication | 
| Drug Highest PhasePending | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Start Date15 May 2025 | 
| Sponsor / Collaborator  [+1]  | 
| Start Date01 May 2025 | 
| Sponsor / Collaborator  [+2]  | 
| Start Date14 Apr 2025 | 
| Sponsor / Collaborator | 

| Drug(Targets) | Indications | Global Highest Phase | 
|---|---|---|
| InflaMab(  NLRP3 ) | Glaucoma More | Preclinical | 
| Ac3IV(  AVPR1A x AVPR1B ) | Diabetes Mellitus More | Preclinical | 
| (Val8)GLP-1(Ulster University)(  GLP-1R ) | Diabetes Mellitus, Type 2 More | Pending | 





